Likewise, Misono says that clinicians and researchers may need to pay greater attention to common risk factors for prostate cancer and suicide, such as depression, pain, and decreased quality of life.
Provenge is a first-of-its-kind therapy that extends life for patients with prostate cancer that has spread but is not yet causing pain or other symptoms.